Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Failure, Acute | 5 | 2020 | 10 | 1.430 |
Why?
|
| Acetaminophen | 4 | 2020 | 19 | 1.310 |
Why?
|
| Neurology | 1 | 2024 | 50 | 0.810 |
Why?
|
| Registries | 4 | 2019 | 294 | 0.440 |
Why?
|
| Rare Diseases | 1 | 2014 | 18 | 0.430 |
Why?
|
| Models, Theoretical | 1 | 2015 | 139 | 0.410 |
Why?
|
| Models, Statistical | 1 | 2014 | 187 | 0.400 |
Why?
|
| Algorithms | 1 | 2014 | 536 | 0.340 |
Why?
|
| Biostatistics | 2 | 2024 | 8 | 0.330 |
Why?
|
| Area Under Curve | 3 | 2019 | 90 | 0.290 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2020 | 7 | 0.290 |
Why?
|
| ROC Curve | 3 | 2019 | 169 | 0.280 |
Why?
|
| Biomedical Research | 2 | 2024 | 178 | 0.240 |
Why?
|
| Databases, Factual | 2 | 2019 | 368 | 0.230 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 853 | 0.230 |
Why?
|
| Research Design | 2 | 2024 | 314 | 0.230 |
Why?
|
| Geriatrics | 1 | 2024 | 86 | 0.200 |
Why?
|
| Humans | 11 | 2024 | 32284 | 0.190 |
Why?
|
| Physical Therapy Modalities | 1 | 2023 | 82 | 0.180 |
Why?
|
| Postural Balance | 1 | 2023 | 142 | 0.170 |
Why?
|
| Adult | 6 | 2022 | 9259 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 186 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2022 | 267 | 0.160 |
Why?
|
| Multiple Organ Failure | 1 | 2020 | 10 | 0.160 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2020 | 15 | 0.160 |
Why?
|
| Middle Aged | 6 | 2020 | 11853 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2019 | 82 | 0.140 |
Why?
|
| Food Supply | 1 | 2019 | 64 | 0.140 |
Why?
|
| Aging | 1 | 2024 | 942 | 0.140 |
Why?
|
| Linear Models | 1 | 2019 | 425 | 0.140 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 556 | 0.130 |
Why?
|
| Prognosis | 2 | 2019 | 1534 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 883 | 0.120 |
Why?
|
| Male | 6 | 2020 | 19443 | 0.120 |
Why?
|
| Female | 6 | 2020 | 19947 | 0.120 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 2015 | 1 | 0.120 |
Why?
|
| Corneal Diseases | 1 | 2015 | 10 | 0.110 |
Why?
|
| Prostheses and Implants | 1 | 2015 | 48 | 0.110 |
Why?
|
| Demography | 1 | 2015 | 101 | 0.110 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 20 | 0.110 |
Why?
|
| Decision Trees | 1 | 2014 | 30 | 0.110 |
Why?
|
| Bioprosthesis | 1 | 2015 | 60 | 0.110 |
Why?
|
| Artificial Intelligence | 1 | 2014 | 63 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2015 | 185 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 132 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2019 | 3628 | 0.100 |
Why?
|
| Aged | 4 | 2024 | 10265 | 0.100 |
Why?
|
| Mitochondria | 1 | 2014 | 211 | 0.090 |
Why?
|
| Obesity | 1 | 2019 | 1111 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2019 | 3416 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2015 | 823 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2020 | 854 | 0.060 |
Why?
|
| Insulin Infusion Systems | 1 | 2022 | 7 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 11 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 23 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 94 | 0.050 |
Why?
|
| Forecasting | 1 | 2023 | 144 | 0.050 |
Why?
|
| Insulin | 1 | 2022 | 359 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 484 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 144 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 413 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 565 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 150 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 955 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 236 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 477 | 0.030 |
Why?
|
| Prosthesis Fitting | 1 | 2015 | 5 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 651 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1479 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2015 | 76 | 0.030 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2014 | 1 | 0.030 |
Why?
|
| tert-Butylhydroperoxide | 1 | 2014 | 4 | 0.030 |
Why?
|
| Electron Transport | 1 | 2014 | 16 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2014 | 20 | 0.030 |
Why?
|
| Oxidants | 1 | 2014 | 15 | 0.030 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2014 | 17 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 743 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 2316 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 757 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2014 | 56 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2014 | 109 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 288 | 0.030 |
Why?
|
| Cell Line | 1 | 2014 | 454 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 622 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1425 | 0.020 |
Why?
|
| United States | 1 | 2019 | 4072 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2240 | 0.020 |
Why?
|
| Mice | 1 | 2014 | 2571 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 3934 | 0.020 |
Why?
|
| Animals | 1 | 2014 | 8199 | 0.010 |
Why?
|